Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey
- PMID: 28589310
- DOI: 10.1007/s00520-017-3772-y
Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey
Abstract
Background/purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a prominent side effect of the treatment of cancer. Despite this frequent complication, there has been no comprehensive review and quality appraisal of CIPN assessments. The purpose of this study is to provide a definitive quality appraisal of CIPN assessment strategies for clinical use.
Methods: Relevant studies were identified through database searches of Medline, Embase, CINAHL, and Cochrane. CIPN assessment strategies from included articles were extracted and initially rated by an oncologist and neurophysiologist according to criteria related to assessment depth, comprehensiveness, appropriateness, and reliability. The six highest scoring assessment strategies were the focus of a two-round Delphi survey of a working party of 32 physicians, nurses, and consumers to achieve consensus on the highest rated assessments for each criterion.
Results: The database search yielded 117 distinct CIPN assessments that were extracted from 2373 articles. Three patient-reported outcome surveys and three clinician-based assessments were included in the Delphi survey. No consensus was generated regarding the best overall CIPN assessment, although good (≥70%) consensus was achieved regarding the best assessment within each criterion. The Participant Neurotoxicity Questionnaire (PNQ) was rated the highest overall and patient-reported outcome (PRO) assessment, while the Total Neuropathy Score clinical version (TNSc) was the highest rated clinician-based assessment.
Conclusions: A diverse range of CIPN assessments currently exists. While several assessments assess CIPN symptoms with adequate comprehensiveness, depth, language, and feasibility, the consensus 'gold standard' clinical assessment remains to be established.
Keywords: Chemotherapy; Neuropathy; Peripheral nervous system diseases; Symptom assessment.
Similar articles
-
Eliciting adverse effects data from participants in clinical trials.Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2. Cochrane Database Syst Rev. 2018. PMID: 29372930 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review.Oncol Nurs Forum. 2017 May 1;44(3):E111-E123. doi: 10.1188/17.ONF.E111-E123. Oncol Nurs Forum. 2017. PMID: 28635977
-
A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms.J Cancer Surviv. 2023 Feb;17(1):254-277. doi: 10.1007/s11764-021-00997-w. Epub 2021 Mar 12. J Cancer Surviv. 2023. PMID: 33710510 Free PMC article.
-
Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With Cancer.J Med Internet Res. 2025 Feb 5;27:e65615. doi: 10.2196/65615. J Med Internet Res. 2025. PMID: 39908091 Free PMC article.
Cited by
-
Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors.J Pain Symptom Manage. 2018 Jul;56(1):88-97. doi: 10.1016/j.jpainsymman.2018.02.021. Epub 2018 Mar 7. J Pain Symptom Manage. 2018. PMID: 29524582 Free PMC article.
-
Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.Neurology. 2021 Aug 17;97(7):e660-e672. doi: 10.1212/WNL.0000000000012300. Epub 2021 Jun 2. Neurology. 2021. PMID: 34078718 Free PMC article.
-
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.Asian Pac J Cancer Prev. 2021 Mar 1;22(3):705-709. doi: 10.31557/APJCP.2021.22.3.705. Asian Pac J Cancer Prev. 2021. PMID: 33773532 Free PMC article. Clinical Trial.
-
Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes.J Clin Med. 2022 Mar 27;11(7):1862. doi: 10.3390/jcm11071862. J Clin Med. 2022. PMID: 35407470 Free PMC article.
-
Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.Support Care Cancer. 2019 Dec;27(12):4753-4762. doi: 10.1007/s00520-019-04771-8. Epub 2019 Apr 10. Support Care Cancer. 2019. PMID: 30972646
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical